Disease Domain | Count |
---|---|
Neoplasms | 1 |
Infectious Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Top 5 Target | Count |
---|---|
PKC(Protein kinase C) | 1 |
Target |
Mechanism PKC stimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Oct 2024 |
Sponsor / Collaborator |
Start Date13 Apr 2023 |
Sponsor / Collaborator |
Start Date03 Nov 2022 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Tigilanol tiglate ( PKC ) | Head and Neck Neoplasms More | Phase 2 |
Anti-inflammatories (Qbiotics) | Inflammation More | Preclinical |
Antibiotics (Qbiotics) | Bacterial Infections and Mycoses More | Preclinical |
EBC-1013 | Varicose Ulcer More | Pending |